Pharmaceuticals & Biotech U.S. Community
US$169.00
FV
4.5% undervalued intrinsic discount7.50%
Revenue growth p.a.
14users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
3 months agoauthor updated this narrative
ST
Equity Analyst and Writer
Industry Tailwinds, Company Headwinds And New Products Will Lead To Stable Revenue Growth
US$133.00
FV
21.3% overvalued intrinsic discount3.00%
Revenue growth p.a.
15users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
3 months agoauthor updated this narrative
WA
Based on Analyst Price Targets
Biote's Innovative Strategies And Expansions Set To Enhance Revenue And Shareholder Value
US$9.59
FV
43.2% undervalued intrinsic discount18.53%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
about 7 hours agoauthor updated this narrative
WA
Based on Analyst Price Targets
EXPAREL's Calculated Expansion And Innovative R&D Bolster Market Dominance Amidst Challenges
US$18.00
FV
20.4% undervalued intrinsic discount-0.30%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
3 days agoauthor updated this narrative
WA
Based on Analyst Price Targets
HELIOGEN's Launch And Scientific Breakthroughs Promise Growth Amid Reimbursement And Legal Challenges
US$12.20
FV
53.7% undervalued intrinsic discount9.83%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
3 days agoauthor updated this narrative
WA
Based on Analyst Price Targets
Unlocking Growth, Navigating Financial Triumphs And Market Expansion In The Pharmaceutical Arena
US$995.42
FV
8.6% undervalued intrinsic discount23.38%
Revenue growth p.a.
2users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
4 days agoauthor updated this narrative
WA
Based on Analyst Price Targets
Decisive Innovations And Cost-Saving Measures Set The Stage For Robust Financial Growth Amidst Market Challenges
US$33.61
FV
13.8% undervalued intrinsic discount5.23%
Revenue growth p.a.
2users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
4 days agoauthor updated this narrative
WA
Based on Analyst Price Targets
LINZESS And Apraglutide Set To Power Through Market Challenges With Strong Growth Prospects
US$11.43
FV
64.5% undervalued intrinsic discount0.32%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
9 days agoauthor updated this narrative
WA
Based on Analyst Price Targets
Rising Costs And Currency Risks Mar Outlook, Yet Calculated Acquisitions And Initiatives Promise Growth
US$15.60
FV
41.7% overvalued intrinsic discount9.02%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
9 days agoauthor updated this narrative